TCR2 Therapeutics Key Executives
This section highlights TCR2 Therapeutics's key executives, including their titles and compensation details.
Find Contacts at TCR2 Therapeutics
(Showing 0 of )
TCR2 Therapeutics Earnings
This section highlights TCR2 Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
$1.48
Stock Price
$58.11M
Market Cap
66
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for TCR2 Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $98.64M | $77.24M | $51.98M | $37.49M | $19.67M |
| General and Administrative Expenses | $24.44M | $22.50M | $16.72M | $13.89M | $6.78M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $24.44M | $22.50M | $16.72M | $13.89M | $6.78M |
| Other Expenses | $30.42M | $- | $- | $- | $- |
| Operating Expenses | $123.08M | $99.74M | $68.70M | $51.38M | $26.45M |
| Cost and Expenses | $123.08M | $99.74M | $68.70M | $51.38M | $26.45M |
| Interest Income | $1.94M | $224.00K | $1.74M | $- | $- |
| Interest Expense | $58.90M | $- | $- | $- | $- |
| Depreciation and Amortization | $63.88M | $2.83M | $1.59M | $862.00K | $419.00K |
| EBITDA | $-89.62M | $-96.92M | $-67.11M | $-50.52M | $-23.83M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-153.50M | $-99.74M | $-68.70M | $-51.38M | $-26.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $1.94M | $224.00K | $1.74M | $3.88M | $2.20M |
| Income Before Tax | $-151.56M | $-99.52M | $-66.96M | $-47.50M | $-24.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $261.00K | $289.00K | $161.00K | $102.00K | $2.20M |
| Net Income | $-151.82M | $-99.81M | $-67.12M | $-47.60M | $-24.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-3.93 | $-2.63 | $-2.40 | $-2.26 | $-1.05 |
| EPS Diluted | $-3.93 | $-2.63 | $-2.40 | $-2.26 | $-1.05 |
| Weighted Average Shares Outstanding | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M |
| Weighted Average Shares Outstanding Diluted | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 | June 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $29.27M | $25.74M | $24.79M | $25.77M | $22.88M | $22.41M | $20.28M | $18.63M | $15.92M | $14.30M | $12.82M | $12.91M | $11.96M | $9.39M | $11.37M | $8.83M | $7.89M | $6.22M | $5.39M | $5.17M |
| General and Administrative Expenses | $8.20M | $5.80M | $6.31M | $6.00M | $6.32M | $5.21M | $5.96M | $5.67M | $5.67M | $4.27M | $4.37M | $3.81M | $4.27M | $4.18M | $3.52M | $3.31M | $2.89M | $2.22M | $1.70M | $1.63M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $8.20M | $5.80M | $6.31M | $6.00M | $6.32M | $5.21M | $5.96M | $5.67M | $5.67M | $4.27M | $4.37M | $3.81M | $4.27M | $4.18M | $3.52M | $3.31M | $2.89M | $2.22M | $1.70M | $1.63M |
| Other Expenses | $4.04M | $30.42M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $37.47M | $31.54M | $31.10M | $31.77M | $29.20M | $27.62M | $26.24M | $24.29M | $21.59M | $18.57M | $17.19M | $16.72M | $16.23M | $13.57M | $14.90M | $12.14M | $10.78M | $8.44M | $7.09M | $6.81M |
| Cost and Expenses | $37.47M | $31.54M | $31.10M | $31.77M | $29.20M | $27.62M | $26.24M | $24.29M | $21.59M | $18.57M | $17.19M | $16.72M | $16.23M | $13.57M | $14.90M | $12.14M | $10.78M | $8.44M | $7.09M | $6.81M |
| Interest Income | $1.11M | $1.01M | $510.00K | $298.00K | $117.00K | $38.00K | $38.00K | $- | $- | $191.00K | $300.00K | $499.00K | $747.00K | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $6.97M | $- | $- | $298.00K | $117.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $8.70M | $59.77M | $890.00K | $704.00K | $706.00K | $851.00K | $773.00K | $690.00K | $513.00K | $478.00K | $441.00K | $367.00K | $306.00K | $304.00K | $258.00K | $165.00K | $135.00K | $116.00K | $115.00K | $112.00K |
| EBITDA | $-32.81M | $-1.66M | $-30.21M | $-31.07M | $-28.50M | $-26.73M | $-25.43M | $-23.57M | $-20.96M | $-17.90M | $-16.45M | $-15.85M | $-15.17M | $-12.42M | $-13.55M | $-10.90M | $-9.77M | $-7.57M | $-6.27M | $-6.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-41.51M | $-61.42M | $-31.10M | $-31.77M | $-29.20M | $-27.58M | $-26.24M | $-24.29M | $-21.59M | $-18.57M | $-17.19M | $-16.72M | $-16.23M | $-13.57M | $-14.90M | $-12.14M | $-10.78M | $-8.44M | $-7.09M | $-6.81M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $1.11M | $1.01M | $510.00K | $298.00K | $117.00K | $38.00K | $38.00K | $32.00K | $116.00K | $191.00K | $300.00K | $499.00K | $747.00K | $846.00K | $1.09M | $1.08M | $872.00K | $751.00K | $702.00K | $622.00K |
| Income Before Tax | $-40.40M | $-60.41M | $-30.59M | $-31.47M | $-29.09M | $-27.58M | $-26.20M | $-24.26M | $-21.48M | $-18.38M | $-16.89M | $-16.22M | $-15.48M | $-12.72M | $-13.81M | $-11.06M | $-9.90M | $-7.69M | $-6.39M | $-6.19M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $3.00K | $96.00K | $1.00K | $128.00K | $36.00K | $160.00K | $42.00K | $51.00K | $36.00K | $75.00K | $31.00K | $28.00K | $27.00K | $102.00K | $1.09M | $1.08M | $872.00K | $751.00K | $702.00K | $622.00K |
| Net Income | $-40.40M | $-60.51M | $-30.59M | $-31.60M | $-29.12M | $-27.74M | $-26.24M | $-24.31M | $-21.51M | $-18.45M | $-16.92M | $-16.25M | $-15.51M | $-12.83M | $-13.81M | $-11.06M | $-9.90M | $-7.69M | $-6.39M | $-6.19M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.03 | $-1.56 | $-0.79 | $-0.82 | $-0.76 | $-0.72 | $-0.69 | $-0.64 | $-0.58 | $-0.55 | $-0.56 | $-0.67 | $-0.65 | $-0.54 | $-0.58 | $-0.46 | $-0.80 | $-0.33 | $-0.43 | $-0.41 |
| EPS Diluted | $-1.03 | $-1.56 | $-0.79 | $-0.82 | $-0.76 | $-0.72 | $-0.69 | $-0.64 | $-0.58 | $-0.55 | $-0.56 | $-0.67 | $-0.65 | $-0.54 | $-0.58 | $-0.46 | $-0.80 | $-0.33 | $-0.43 | $-0.41 |
| Weighted Average Shares Outstanding | 39.22M | 38.81M | 38.62M | 38.57M | 38.51M | 38.29M | 38.20M | 38.18M | 37.06M | 33.45M | 30.34M | 24.08M | 24.01M | 23.96M | 23.87M | 23.82M | 12.33M | 23.19M | 15.01M | 15.01M |
| Weighted Average Shares Outstanding Diluted | 39.22M | 38.81M | 38.62M | 38.57M | 38.51M | 38.29M | 38.20M | 38.18M | 37.06M | 33.45M | 30.34M | 24.08M | 24.01M | 23.96M | 23.87M | 23.82M | 12.33M | 23.19M | 15.01M | 15.01M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $32.75M | $222.56M | $94.16M | $65.30M | $47.67M |
| Short Term Investments | $116.43M | $43.03M | $133.83M | $92.83M | $75.49M |
| Cash and Short Term Investments | $149.18M | $265.59M | $227.99M | $158.12M | $123.17M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $5.16M | $10.53M | $7.55M | $5.06M | $2.33M |
| Total Current Assets | $177.62M | $276.13M | $235.54M | $163.19M | $125.49M |
| Property Plant Equipment Net | $28.68M | $45.36M | $10.01M | $4.93M | $1.64M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.94M | $1.89M | $644.00K | $417.00K | $2.30M |
| Total Non-Current Assets | $30.61M | $47.24M | $10.66M | $5.34M | $3.94M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $208.24M | $323.37M | $246.19M | $168.53M | $129.43M |
| Account Payables | $2.79M | $2.14M | $2.45M | $2.48M | $2.66M |
| Short Term Debt | $50.45M | $3.37M | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $12.26M | $- | $- | $- |
| Other Current Liabilities | $10.82M | $830.00K | $6.39M | $5.05M | $2.80M |
| Total Current Liabilities | $64.06M | $18.61M | $8.84M | $7.53M | $5.46M |
| Long Term Debt | $3.32M | $23.00M | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $293.00K | $807.00K | $546.00K | $209.66M |
| Total Non-Current Liabilities | $3.32M | $23.29M | $807.00K | $546.00K | $209.66M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $67.38M | $41.89M | $9.65M | $8.08M | $215.13M |
| Preferred Stock | $- | $- | $- | $168.53M | $72.98M |
| Common Stock | $4.00K | $4.00K | $3.00K | $2.00K | $- |
| Retained Earnings | $-501.34M | $-349.52M | $-249.72M | $-182.59M | $-85.59M |
| Accumulated Other Comprehensive Income Loss | $-445.00K | $-13.00K | $63.00K | $142.00K | $-106.00K |
| Other Total Stockholders Equity | $642.64M | $631.01M | $486.20M | $174.37M | $-72.98M |
| Total Stockholders Equity | $140.86M | $281.48M | $236.55M | $160.45M | $-85.70M |
| Total Equity | $140.86M | $281.48M | $236.55M | $160.45M | $-85.70M |
| Total Liabilities and Stockholders Equity | $208.24M | $323.37M | $246.19M | $168.53M | $129.43M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $208.24M | $323.37M | $246.19M | $168.53M | $129.43M |
| Total Investments | $116.43M | $43.03M | $133.83M | $92.83M | $75.49M |
| Total Debt | $53.76M | $26.36M | $- | $- | $- |
| Net Debt | $21.02M | $-196.20M | $-94.16M | $-65.30M | $-47.67M |
Balance Sheet Charts
| Breakdown | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 | December 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $14.45M | $32.75M | $54.01M | $44.21M | $74.12M | $222.56M | $262.50M | $248.79M | $218.28M | $94.16M | $101.61M | $49.70M | $31.09M | $65.30M | $49.32M | $40.98M | $46.41M | $47.67M | $107.77M | $19.81M |
| Short Term Investments | $95.86M | $116.43M | $121.98M | $162.03M | $158.07M | $43.03M | $33.24M | $68.55M | $115.00M | $133.83M | $145.11M | $75.12M | $95.02M | $92.83M | $111.69M | $128.65M | $115.25M | $75.49M | $23.23M | $- |
| Cash and Short Term Investments | $110.31M | $149.18M | $175.99M | $206.24M | $232.19M | $265.59M | $295.74M | $317.35M | $333.28M | $227.99M | $246.72M | $124.81M | $126.12M | $158.12M | $161.00M | $169.63M | $161.66M | $123.17M | $131.00M | $19.81M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $8.82M | $5.16M | $8.09M | $9.59M | $15.12M | $10.53M | $7.48M | $7.88M | $9.69M | $7.55M | $7.51M | $8.96M | $6.84M | $5.06M | $5.61M | $6.05M | $3.93M | $2.33M | $392.00K | $892.00K |
| Total Current Assets | $140.49M | $177.62M | $184.08M | $215.83M | $247.30M | $276.13M | $303.22M | $325.23M | $342.97M | $235.54M | $254.23M | $133.78M | $132.96M | $163.19M | $166.62M | $175.68M | $165.59M | $125.49M | $131.39M | $20.70M |
| Property Plant Equipment Net | $9.15M | $28.68M | $86.79M | $90.00M | $74.00M | $45.36M | $41.68M | $41.28M | $51.84M | $10.01M | $6.20M | $5.96M | $5.22M | $4.93M | $4.46M | $3.17M | $1.94M | $1.64M | $1.79M | $1.03M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $14.54M | $- | $8.01M | $11.12M | $30.05M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.87M | $1.94M | $2.06M | $2.21M | $1.95M | $1.89M | $1.82M | $1.63M | $1.37M | $644.00K | $417.00K | $648.00K | $587.00K | $417.00K | $417.00K | $290.00K | $290.00K | $2.30M | $1.49M | $310.00K |
| Total Non-Current Assets | $11.02M | $30.61M | $88.85M | $92.21M | $75.94M | $47.24M | $43.51M | $42.91M | $53.21M | $10.66M | $6.62M | $6.61M | $20.35M | $5.34M | $12.89M | $14.58M | $32.27M | $3.94M | $3.28M | $1.34M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $151.51M | $208.24M | $272.93M | $308.04M | $323.25M | $323.37M | $346.72M | $368.14M | $396.18M | $246.19M | $260.85M | $140.38M | $153.30M | $168.53M | $179.51M | $190.26M | $197.86M | $129.43M | $134.67M | $22.04M |
| Account Payables | $6.32M | $2.79M | $2.96M | $5.47M | $4.48M | $2.14M | $4.38M | $4.82M | $3.83M | $2.45M | $2.95M | $2.99M | $3.18M | $2.48M | $3.62M | $4.04M | $2.83M | $2.66M | $1.51M | $427.00K |
| Short Term Debt | $3.27M | $50.45M | $20.55M | $20.57M | $16.93M | $3.37M | $3.48M | $3.59M | $2.11M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $37.88M | $10.82M | $13.19M | $12.53M | $9.45M | $13.09M | $8.65M | $6.53M | $4.58M | $6.39M | $4.90M | $3.37M | $2.95M | $5.05M | $4.26M | $3.12M | $2.53M | $2.80M | $2.28M | $804.00K |
| Total Current Liabilities | $47.47M | $64.06M | $36.69M | $38.57M | $30.87M | $18.61M | $16.52M | $14.95M | $10.52M | $8.84M | $7.85M | $6.36M | $6.13M | $7.53M | $7.88M | $7.16M | $5.36M | $5.46M | $3.79M | $1.23M |
| Long Term Debt | $2.71M | $3.32M | $37.68M | $43.21M | $36.75M | $23.00M | $23.64M | $24.05M | $35.01M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $313.00K | $293.00K | $299.00K | $257.00K | $892.00K | $807.00K | $635.00K | $609.00K | $583.00K | $546.00K | $474.00K | $464.00K | $455.00K | $209.66M | $412.00K | $47.13M |
| Total Non-Current Liabilities | $2.71M | $3.32M | $37.68M | $43.21M | $37.06M | $23.29M | $23.93M | $24.30M | $35.90M | $807.00K | $635.00K | $609.00K | $583.00K | $546.00K | $474.00K | $464.00K | $455.00K | $209.66M | $412.00K | $47.13M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $50.18M | $67.38M | $74.38M | $81.78M | $67.93M | $41.89M | $40.45M | $39.25M | $46.42M | $9.65M | $8.49M | $6.97M | $6.71M | $8.08M | $8.36M | $7.62M | $5.81M | $215.13M | $4.20M | $48.36M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $140.38M | $153.30M | $- | $179.51M | $190.26M | $197.86M | $- | $- | $- |
| Common Stock | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $- | $2.00K | $- |
| Retained Earnings | $-541.74M | $-501.34M | $-440.84M | $-410.25M | $-378.64M | $-349.52M | $-321.78M | $-295.54M | $-271.23M | $-249.72M | $-231.26M | $-214.34M | $-198.10M | $-182.59M | $-169.76M | $-155.96M | $-144.90M | $-85.59M | $-75.03M | $-26.32M |
| Accumulated Other Comprehensive Income Loss | $-188.00K | $-445.00K | $-596.00K | $-671.00K | $-344.00K | $-13.00K | $-15.00K | $-19.00K | $-44.00K | $63.00K | $191.00K | $402.00K | $-462.00K | $142.00K | $230.00K | $212.00K | $1.00K | $-106.00K | $-3.00K | $- |
| Other Total Stockholders Equity | $643.26M | $642.64M | $639.98M | $637.17M | $634.30M | $631.01M | $628.06M | $624.45M | $621.02M | $486.20M | $483.43M | $206.97M | $191.84M | $342.90M | $161.18M | $148.12M | $139.08M | $- | $205.50M | $- |
| Total Stockholders Equity | $101.33M | $140.86M | $198.55M | $226.26M | $255.32M | $281.48M | $306.27M | $328.89M | $349.75M | $236.55M | $252.36M | $133.41M | $146.59M | $160.45M | $171.15M | $182.64M | $192.05M | $-85.70M | $130.46M | $-26.32M |
| Total Equity | $101.33M | $140.86M | $198.55M | $226.26M | $255.32M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $151.51M | $208.24M | $272.93M | $308.04M | $323.25M | $323.37M | $346.72M | $368.14M | $396.18M | $246.19M | $260.85M | $140.38M | $153.30M | $168.53M | $179.51M | $190.26M | $197.86M | $129.43M | $134.67M | $22.04M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $151.51M | $208.24M | $272.93M | $308.04M | $323.25M | $323.37M | $346.72M | $368.14M | $396.18M | $246.19M | $260.85M | $140.38M | $153.30M | $168.53M | $179.51M | $190.26M | $197.86M | $129.43M | $134.67M | $22.04M |
| Total Investments | $95.86M | $116.43M | $121.98M | $162.03M | $158.07M | $43.03M | $33.24M | $68.55M | $115.00M | $133.83M | $145.11M | $75.12M | $109.56M | $92.83M | $119.70M | $139.77M | $145.30M | $75.49M | $23.23M | $- |
| Total Debt | $5.98M | $53.76M | $58.23M | $63.78M | $53.68M | $26.36M | $27.12M | $27.64M | $37.12M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-8.47M | $21.02M | $4.22M | $19.57M | $-20.43M | $-196.20M | $-235.38M | $-221.15M | $-181.15M | $-94.16M | $-101.61M | $-49.70M | $-31.09M | $-65.30M | $-49.32M | $-40.98M | $-46.41M | $-47.67M | $-107.77M | $-19.81M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-151.82M | $-99.81M | $-67.12M | $-47.60M | $-24.25M |
| Depreciation and Amortization | $3.05M | $2.83M | $1.59M | $862.00K | $419.00K |
| Deferred Income Tax | $-293.00K | $99.00K | $131.00K | $- | $- |
| Stock Based Compensation | $11.38M | $12.27M | $8.49M | $6.70M | $2.13M |
| Change in Working Capital | $9.58M | $1.62M | $872.00K | $-1.10M | $3.20M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $1.17M | $-771.00K | $451.00K | $-179.00K | $2.22M |
| Other Working Capital | $8.41M | $2.39M | $421.00K | $-920.00K | $975.00K |
| Other Non Cash Items | $26.65M | $1.40M | $-702.00K | $-225.00K | $-278.00K |
| Net Cash Provided by Operating Activities | $-101.46M | $-81.60M | $-56.74M | $-41.36M | $-18.78M |
| Investments in Property Plant and Equipment | $-15.45M | $-11.45M | $-7.16M | $-3.88M | $-1.02M |
| Acquisitions Net | $15.45M | $351.00K | $7.78M | $4.15M | $1.03M |
| Purchases of Investments | $-267.52M | $-50.73M | $-152.81M | $-126.26M | $-97.81M |
| Sales Maturities of Investments | $194.49M | $140.62M | $111.04M | $109.72M | $22.49M |
| Other Investing Activities | $-15.45M | $-351.00K | $-7.78M | $-4.15M | $-1.03M |
| Net Cash Used for Investing Activities | $-88.49M | $78.45M | $-48.94M | $-20.41M | $-76.34M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $256.00K | $131.33M | $133.57M | $79.13M | $125.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $125.00K | $132.14M | $134.70M | $79.52M | $122.98M |
| Net Cash Used Provided by Financing Activities | $125.00K | $132.14M | $134.70M | $79.52M | $122.98M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-189.82M | $128.98M | $29.02M | $17.75M | $27.86M |
| Cash at End of Period | $33.90M | $223.72M | $94.74M | $65.71M | $47.67M |
| Cash at Beginning of Period | $223.72M | $94.74M | $65.71M | $47.96M | $19.81M |
| Operating Cash Flow | $-101.46M | $-81.60M | $-56.74M | $-41.36M | $-18.78M |
| Capital Expenditure | $-15.45M | $-11.45M | $-7.16M | $-3.88M | $-1.02M |
| Free Cash Flow | $-116.91M | $-93.05M | $-63.90M | $-45.24M | $-19.80M |
Cash Flow Charts
| Breakdown | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 | June 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-40.40M | $-60.51M | $-30.59M | $-31.60M | $-29.12M | $-27.74M | $-26.24M | $-24.31M | $-21.51M | $-18.45M | $-16.92M | $-16.25M | $-15.51M | $-12.83M | $-13.81M | $-11.06M | $-9.90M | $-7.69M | $-6.39M | $-6.19M |
| Depreciation and Amortization | $615.00K | $746.00K | $890.00K | $704.00K | $706.00K | $851.00K | $773.00K | $690.00K | $513.00K | $478.00K | $441.00K | $367.00K | $306.00K | $304.00K | $258.00K | $165.00K | $135.00K | $116.00K | $115.00K | $112.00K |
| Deferred Income Tax | $- | $- | $- | $-314.00K | $21.00K | $-6.00K | $42.00K | $27.00K | $36.00K | $45.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $579.00K | $2.66M | $2.69M | $2.85M | $3.18M | $2.74M | $3.19M | $3.22M | $3.12M | $2.31M | $2.07M | $2.06M | $2.06M | $2.10M | $2.01M | $1.44M | $1.14M | $845.00K | $655.00K | $350.00K |
| Change in Working Capital | $-3.37M | $5.09M | $1.44M | $8.99M | $-5.94M | $104.00K | $2.65M | $1.08M | $-2.22M | $2.83M | $3.51M | $-2.36M | $-3.10M | $50.00K | $1.51M | $-582.00K | $-2.08M | $357.00K | $1.11M | $1.10M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $3.53M | $1.80M | $244.00K | $-2.64M | $1.76M | $-2.84M | $-521.00K | $903.00K | $1.68M | $-159.00K | $581.00K | $-574.00K | $603.00K | $-668.00K | $309.00K | $581.00K | $-401.00K | $1.66M | $-597.00K | $944.00K |
| Other Working Capital | $-6.90M | $3.29M | $1.19M | $11.63M | $-7.69M | $2.94M | $3.17M | $176.00K | $-3.90M | $2.98M | $2.93M | $-1.79M | $-3.70M | $718.00K | $1.20M | $-1.16M | $-1.67M | $-1.30M | $1.71M | $156.00K |
| Other Non Cash Items | $2.57M | $27.05M | $-263.00K | $-160.00K | $20.00K | $24.05M | $209.00K | $253.00K | $164.00K | $-702.00K | $86.00K | $164.00K | $-164.00K | $55.00K | $-28.00K | $-121.00K | $-131.00K | $-97.00K | $-107.00K | $-56.00K |
| Net Cash Provided by Operating Activities | $-40.01M | $-24.96M | $-25.84M | $-19.53M | $-31.13M | $58.32M | $-19.38M | $-19.04M | $-19.90M | $-13.50M | $-10.82M | $-16.01M | $-16.41M | $-10.31M | $-10.06M | $-10.16M | $-10.83M | $-6.47M | $-4.62M | $-4.68M |
| Investments in Property Plant and Equipment | $-158.00K | $-2.44M | $-4.82M | $-6.21M | $-1.98M | $5.18M | $-2.35M | $-821.00K | $-1.49M | $-4.64M | $-1.29M | $-725.00K | $-504.00K | $-819.00K | $-2.12M | $-753.00K | $-188.00K | $-81.00K | $-166.00K | $-404.00K |
| Acquisitions Net | $- | $15.45M | $- | $- | $3.08M | $- | $- | $- | $1.80M | $7.16M | $- | $- | $597.00K | $3.88M | $- | $- | $433.00K | $- | $- | $- |
| Purchases of Investments | $-13.70M | $-51.90M | $-29.61M | $-37.62M | $-148.38M | $-9.99M | $- | $- | $-40.73M | $9.34M | $-99.14M | $-15.05M | $-47.96M | $273.00K | $-19.97M | $-19.94M | $-86.63M | $-61.77M | $-3.70M | $-18.97M |
| Sales Maturities of Investments | $35.00M | $58.00M | $70.00M | $33.50M | $32.99M | $- | $35.10M | $46.23M | $59.29M | $1.12M | $28.94M | $50.36M | $30.62M | $26.73M | $40.37M | $25.80M | $16.82M | $9.50M | $7.46M | $5.53M |
| Other Investing Activities | $543.00K | $-15.45M | $- | $- | $-3.08M | $-11.97M | $- | $- | $-1.80M | $-7.16M | $- | $- | $-597.00K | $-3.88M | $- | $- | $-433.00K | $3.00K | $-3.00K | $- |
| Net Cash Used for Investing Activities | $21.69M | $3.66M | $35.56M | $-10.33M | $-117.37M | $-16.78M | $32.76M | $45.41M | $17.06M | $5.82M | $-71.50M | $34.58M | $-17.84M | $26.19M | $18.28M | $5.11M | $-70.00M | $-52.35M | $3.60M | $-13.85M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $34.00K | $256.00K | $- | $- | $- | $- | $- | $- | $131.33M | $1.00K | $133.57M | $- | $- | $11.00K | $-1.09M | $- | $80.21M | $125.00M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $24.00K | $41.00K | $72.00K | $-47.00K | $59.00K | $131.00K | $343.00K | $4.15M | $127.51M | $387.00K | $134.23M | $29.00K | $50.00K | $103.00K | $236.00K | $-375.00K | $79.56M | $-1.28M | $-755.00K | $4.95M |
| Net Cash Used Provided by Financing Activities | $24.00K | $41.00K | $72.00K | $-47.00K | $59.00K | $131.00K | $343.00K | $4.15M | $127.51M | $387.00K | $134.23M | $29.00K | $50.00K | $103.00K | $236.00K | $-375.00K | $79.56M | $-1.28M | $-755.00K | $4.95M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $-81.60M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-290.00K | $- |
| Net Change in Cash | $-18.30M | $-21.26M | $9.79M | $-29.91M | $-148.44M | $-39.93M | $13.72M | $30.52M | $124.68M | $-7.29M | $51.92M | $18.60M | $-34.20M | $15.98M | $8.46M | $-5.42M | $-1.27M | $-60.09M | $-2.07M | $-13.58M |
| Cash at End of Period | $15.60M | $33.90M | $55.16M | $45.36M | $75.28M | $223.72M | $263.65M | $249.93M | $219.42M | $94.74M | $102.03M | $50.11M | $31.51M | $65.71M | $49.73M | $41.27M | $46.70M | $47.67M | $107.77M | $109.83M |
| Cash at Beginning of Period | $33.90M | $55.16M | $45.36M | $75.28M | $223.72M | $263.65M | $249.93M | $219.42M | $94.74M | $102.03M | $50.11M | $31.51M | $65.71M | $49.73M | $41.27M | $46.70M | $47.96M | $107.77M | $109.83M | $123.42M |
| Operating Cash Flow | $-40.01M | $-24.96M | $-25.84M | $-19.53M | $-31.13M | $58.32M | $-19.38M | $-19.04M | $-19.90M | $-13.50M | $-10.82M | $-16.01M | $-16.41M | $-10.31M | $-10.06M | $-10.16M | $-10.83M | $-6.47M | $-4.62M | $-4.68M |
| Capital Expenditure | $-158.00K | $-2.44M | $-4.82M | $-6.21M | $-1.98M | $5.18M | $-2.35M | $-821.00K | $-1.49M | $-4.64M | $-1.29M | $-725.00K | $-504.00K | $-819.00K | $-2.12M | $-753.00K | $-188.00K | $-81.00K | $-166.00K | $-404.00K |
| Free Cash Flow | $-40.17M | $-27.40M | $-30.66M | $-25.74M | $-33.11M | $63.50M | $-21.73M | $-19.86M | $-21.39M | $-18.14M | $-12.11M | $-16.74M | $-16.91M | $-11.13M | $-12.18M | $-10.91M | $-11.02M | $-6.55M | $-4.78M | $-5.08M |
TCR2 Therapeutics Dividends
Explore TCR2 Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
TCR2 Therapeutics News
Read the latest news about TCR2 Therapeutics, including recent articles, headlines, and updates.
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gavo-cel for the treatment of patients with mesothelin tumors; Focus shift more towards targeting ovarian cancer patients with expected data 2nd half of 2023.
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.
TCR² Therapeutics: Betting On A Solid Reversal
TCR² Therapeutics is a company developing two lead oncology drug candidates targeting mesothelin, a protein expressed on different tumors. Its lead candidate gavo-cel, or TC-210, has presented strong data so far in different solid tumors, including tumor regression in 94% of evaluable patients and a manageable safety profile.
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate at two upcoming conferences in June in New York.
TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 at 1:40PM E.T. using a virtual platform.
Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks
TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10th at 7:00AM E.T. using a virtual platform.
TCR² Therapeutics to Host R&D Day on October 20, 2021
CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m. ET on Wednesday, October 20, 2021.
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio webcast on Friday, September 17, 2021 at 9:00am E.T. to discuss extended data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.
TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will present an update on Company progress at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13th at 7:00AM E.T. using a virtual platform.
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Orphan Drug Designation (ODD) to gavo-cel for the treatment of cholangiocarcinoma. New clinical data from the dose escalation portion of the Phase 1/2 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors will be highlighted as part of an oral presentation at the European Society for Medical Oncology on September 17 at 14:20 CEST (8:20AM EST) and will include data for gavo-cel in malignant mesothelioma, ovarian cancer and cholangiocarcinoma.
TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors
CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Directors. Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegde's arrival, Patrick Baeuerle, Ph.D., will be stepping down from the Board of Directors effective August 24, 2021 but will continue to serve TCR2 in an advisory capacity.
TCR² Therapeutics Announces Upcoming Medical Meetings Update
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that their interim update on the Phase 1/2 clinical trial of gavo-cel will be featured in the official Press Programme at the European Society for Medical Oncology (ESMO). Additionally, due to TCR2 opting to not present its accepted featured poster presentation on September 8, 2021 at the World Conference on Lung Cancer (WCLC), the Company was notified by the WCLC of their decision to withdraw its abstract titled “Phase 1 Trial of Gavocabtagene Autoleucel (gavo-cel, TC-210) In Refractory Mesothelin-Expressing Solid Tumors.”
TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid tumors, today announced the appointment of Peter Olagunju as Chief Technical Officer where he will oversee process development, manufacturing, quality control and technical operations for the Company's TRuC-T cell programs and emerging pipeline.
TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.
TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 11:20am E.T. using a virtual platform.
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that clinical and translational data from the dose escalation portion of the Company's Phase 1/2 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors will be presented today at the American Association for Cancer Research (AACR) Virtual Annual Meeting in an e-poster titled “Preliminary Safety and Efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T Cell Receptor Fusion Construct (TRuC®), in Patients with Treatment Refractory Mesothelin Overexpressing Solid Tumors.” In addition, preclinical data from the Company's autologous CD70 and allogeneic mesothelin TRuC-T cells will be highlighted in e-posters in the Adoptive Cell Therapy session at AACR.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for TCRR.